This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.
Immune checkpoint inhibitors have proven to be an effective weapon against many solid tumors, but a large proportion of patients do not show a clinical benefit upon treatment. While studies have identified genomic or transcriptomic features responsible to some extent for the lack of response, major advancements in mass spectrometry-based proteomics have only recently enabled comprehensive functional analysis of the final gene products on an unprecedented scale, enabling quantitative and clinically relevant analysis of response mechanisms.
In this webinar, Paolo A. Ascierto, MD of Italy’s National Tumor Institute and Kamil Sklodowski of Biognosys will elaborate on the promise of proteomics for addressing the unmet medical needs of melanoma patients undergoing immunotherapy.
They will discuss data from a joint project in which cancer tissue samples from late-stage melanoma patients prior to treatment with immune checkpoint inhibitors were analyzed using the Biognosys HRM discovery platform.
They will share the clinical outcomes as well as the associated proteomic profiles of more than 8,500 identified and quantified proteins, providing a full picture of the capabilities of next-generation proteomics.
About The Series: Next-Generation Proteomics for Precision Oncology
This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.